Are we closer to achieving precision medicine for migraine treatment? A narrative review

Otros/as autores/as

Institut Català de la Salut

[Ihara K] Department of Neurology, Keio University School of Medicine, Tokyo, Japan. Neurology Department, Japanese Red Cross Ashikaga Hospital, Ashikaga, Japan. [Casillo F] Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino ICOT, Latina, Italy. [Dahshan A] Department of Neurology, Cairo University, Cairo, Egypt. [Genç H] Department of Neurology, Gaziantep City Hospital, Gaziantep, Türkiye. [Jusupova A, Karbozova K] Department of Neurology and Clinical Genetics, Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan. [Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain

Vall d'Hebron Barcelona Hospital Campus

Fecha de publicación

2024-10-28T11:55:42Z

2024-10-28T11:55:42Z

2024-09



Resumen

Migraine; Prediction; Treatment


Migraña; Predicción; Tratamiento


Migranya; Predicció; Tractament


Background The term ‘precision medicine’ encompasses strategies to optimize diagnosis and outcome prediction and to tailor treatment for individual patients, in consideration of their unique characteristics. The greater availability of multifaceted datasets and strategies to model such data have made precision medicine increasingly possible in recent years. Precision medicine is especially needed in the migraine field since the response to migraine treatments is not universal amongst all individuals with migraine. Objective To provide a narrative review describing contributions to achieving precision medicine for migraine treatment. Methods A search of PubMed for English language articles of human participants published from 2005 to January 2024 was conducted to identify articles that reported research contributing to precision medicine for migraine treatment. The published literature was categorized and summarized according to the type of data that were included: clinical phenotypes, genomics, proteomics, physiologic measures, and brain imaging. Results Published studies have investigated characteristics associated with acute and preventive treatment responses, such as nonsteroidal anti-inflammatory drugs, triptans, onabotulinumtoxinA, and anti-calcitonin gene-related peptide monoclonal antibodies, in patients with episodic or chronic migraine. There is evidence that clinical, genetic, epigenetic, proteomic, physiologic, and brain imaging features might associate with migraine treatment outcomes, although inconsistencies for such findings clearly exist. Conclusions The published literature suggests that there are clinical and biological features which associate with, and might be useful for predicting, migraine treatment responses. To achieve precision medicine for migraine treatment, further research is needed that validates and expands on existing findings and tests the accuracy and value of migraine treatment prediction models in clinical settings.

Tipo de documento

Artículo


Versión publicada

Lengua

Inglés

Publicado por

SAGE Publications

Documentos relacionados

Cephalalgia;44(9)

https://doi.org/10.1177/03331024241281518

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

Attribution-NonCommercial 4.0 International

http://creativecommons.org/licenses/by-nc/4.0/

Este ítem aparece en la(s) siguiente(s) colección(ones)